Metis TechBio Co., Ltd. 劑泰科技 (北 京 ) 股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 免責聲明：本申請版本已於2026年2月12日以保密形式提交。 Metis TechBio Co., Ltd. 劑泰科技（北京）股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員 表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長 註冊的本公司招股章程作出投資決定，招股章程的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根 據本文件中的資料作出任 ...

Core Viewpoint - The article discusses the upcoming IPO of Jitai Technology, a biotech company focused on AI-driven nanomaterials, which is expected to soon disclose its PHIP documents and complete its listing on the Hong Kong Stock Exchange [3]. Company Overview - Jitai Technology was founded in 2020 by Dr. Chen Hongmin, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Lai Caida and Dr. Wang Wenshou [3]. - The company specializes in targeted drug delivery and discovery technologies to help combat diseases and aging, aiming to restore health and vitality [3]. Technological Innovations - Jitai Technology has developed the world's first AI-driven nanodelivery platform, NanoForge, and possesses the largest global library of LNP (lipid nanoparticles) with over 10 million variants [4]. - The company has created three core solutions based on NanoForge: AiLNP (AI nanodelivery system design platform), AiRNA (AI mRNA sequence design platform), and AiTEM (AI small molecule formulation design platform) [4]. - Jitai Technology has achieved breakthroughs in targeted delivery to eight key organs or tissues, addressing challenges in multi-organ and multi-tissue targeting, providing drug opportunities for various diseases including tumors and neurodegenerative disorders [4]. Clinical Developments - The pipeline product MTS-004 is China's first AI-enabled new drug that has completed Phase III clinical trials, potentially filling a gap in the PBA treatment field and improving the quality of life for patients with conditions like ALS and swallowing difficulties [4]. - The company is also developing a new generation of immunotherapy strategies through its innovative "rocket + satellite" delivery paradigm, with the pipeline product MTS-105 recognized as an orphan drug by the FDA, aiming to be the first mRNA-encoded TCE therapy for solid tumors globally [4]. Investment and Market Position - Since its establishment, Jitai Technology has secured over 2.5 billion RMB in investments from notable institutions including Jingtaitech, Fengrui Capital, Sequoia China, and others [4]. - The article notes that besides Jitai Technology, several other AI pharmaceutical companies are seeking or have confidentially submitted listing applications to the Hong Kong Stock Exchange [5].

Core Insights - JieTai Technology announced that its AI-driven small molecule formulation optimization platform AiTEM has successfully reached the primary endpoint of Phase III clinical trials for the candidate drug MTS-004, making it the first AI-enabled formulation new drug to complete Phase III trials in China [1][2] - MTS-004 is the first and currently the only drug in China to complete Phase III clinical trials for PBA (Pseudobulbar Affect), addressing a significant gap in the domestic treatment landscape for this condition [1][3] Summary by Sections Drug Development and Clinical Trials - MTS-004 is an innovative oral treatment candidate for PBA, designed as an orally disintegrating tablet (ODT) that dissolves quickly in the mouth without water, improving patient experience and adherence [1][3] - The AiTEM platform, powered by JieTai's proprietary AI nano-delivery platform NanoForge, significantly reduced the preclinical formulation optimization cycle from the industry average of 1-2 years to just 3 months [2] - The Phase III clinical trial involved 264 participants over 9.5 months, led by Professor Fan Dongsheng from Peking University Third Hospital, and included multiple centers across China [2] Clinical Efficacy and Safety - MTS-004 demonstrated good overall safety and clear efficacy in treating PBA secondary to neurological diseases, with statistically significant reductions in average attack frequency after 12 weeks of treatment [3] - The drug showed improvements in various assessments, including CNS-LS scores, CGI-C, PGI-C evaluations, and SF-36 mental health index, indicating enhanced emotional control and quality of life for patients [3] Future Prospects - JieTai plans to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for MTS-004 in 2026, with potential expansion into indications for swallowing disorders post-approval [3] - The CEO of JieTai emphasized the role of AI in accelerating clinical treatment and addressing unmet patient needs, highlighting the successful completion of the drug's development cycle as a foundation for future projects [4]

Core Insights - The company JieTai Technology announced that its AI-driven small molecule formulation optimization platform AiTEM has successfully achieved the primary endpoint of Phase III clinical trials for the candidate drug MTS-004, making it the first AI-enabled formulation new drug to complete Phase III trials in China [1][2] - MTS-004 is the first and currently the only drug in China to complete Phase III clinical trials for Pseudobulbar Affect (PBA), addressing a significant gap in the domestic treatment landscape for PBA [1][3] Company Overview - MTS-004 is a novel oral treatment candidate for PBA, designed as an orally disintegrating tablet (ODT) that dissolves quickly in the mouth without the need for water, improving patient experience and adherence to treatment [1][2] - The AiTEM platform utilizes JieTai's proprietary AI nano-delivery platform NanoForge, employing specialized algorithms for drug formulation design and optimization, significantly reducing the preclinical formulation optimization cycle from the industry average of 1-2 years to just 3 months [2] Clinical Trial Details - The Phase III clinical trial was led by Dr. Fan Dongsheng, a renowned expert in neurodegenerative diseases, and involved a double-blind, randomized, placebo-controlled multi-center study assessing the efficacy and safety of MTS-004 in PBA patients secondary to various neurological conditions [2] - A total of 264 participants were enrolled over a period of 9.5 months, with the trial conducted across 48 clinical centers, including prestigious hospitals such as Peking University Third Hospital and Xuanwu Hospital [2] Efficacy and Safety - MTS-004 demonstrated good overall safety and clear efficacy in treating PBA secondary to neurological diseases, significantly reducing the average frequency of PBA episodes after 12 weeks of treatment, with statistically significant differences observed [3] - The treatment effects were noted as early as the second week, with improvements in emotional control and quality of life measured by various scales, including CNS-LS scores and SF-36 mental health index [3] Future Plans - The company plans to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for MTS-004 for PBA indications in 2026, with intentions to explore potential expansion into swallowing disorder treatments post-approval [3]

Core Insights - The company, Jitai Technology, has launched the world's first AI-driven nano delivery platform, NanoForge, which integrates quantum chemistry and molecular dynamics simulations for drug delivery optimization [1][2] - NanoForge enables a closed-loop process from molecular generation to formulation design, leveraging a large-scale library of over 10 million LNP lipid structures [1][2] - Jitai Technology has developed three major solutions based on NanoForge: AiLNP, AiRNA, and AiTEM, focusing on nucleic acid delivery, mRNA sequence design, and small molecule formulation design respectively [1][2] Company Developments - Jitai Technology has identified LNP targeted delivery for eight organs or tissues, with over 100 authorized and filed patent applications [2] - The company has successfully developed more than 10 pipeline projects, producing 7 preclinical candidates and advancing 4 clinical projects, with the fastest pipeline reaching the pre-NDA stage [2] - The CEO of Jitai Technology emphasized the shift from biotechnology to tech-driven biology, highlighting the efficiency and technological breakthroughs achieved through the integration of large model innovations and iterative experiments [2] Financial and Strategic Moves - In August, Jitai Technology completed a Series D financing round, raising a total of 400 million yuan, led by the Beijing Pharmaceutical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [2] - The funds raised will accelerate the company's strategic initiatives, including platform automation upgrades, advancement of self-developed product pipelines, deepening international collaborations, and attracting high-end talent [2]